Designing Longevity
Skip to main content

Short Bowel Syndrome and Specialist Care

Short bowel syndrome can limit the small intestine’s ability to absorb enough fluid and nutrients. Specialist care centers on hydration and nutrition. Teduglutide has a labeled role for patients ages 1 and older who depend on nutrition or fluids delivered into a vein.

Sources reviewed November 13, 2026 · How we work

What intestinal rehabilitation addresses

Short bowel syndrome often follows surgical removal of part of the small intestine. Care varies with the remaining bowel and how much it absorbs. Teams can adjust food, fluid and electrolyte support, tube feeding or parenteral nutrition, and monitor complications.

Parenteral support delivers fluid or nutrients into a vein. A specialist can explain what measures indicate that someone is absorbing more and whether a change in support is safe.

Sources for this section

Gattex (teduglutide) 5 mg vial

Teduglutide is a glucagon-like peptide-2 (GLP-2) analog that helps the remaining intestine absorb fluids and nutrients. In one 24-week adult trial, 27 of 43 people on teduglutide and 13 of 43 on placebo reached the study response of at least a 20% reduction in weekly parenteral support at weeks 20 and 24. The measured outcome was reduced support volume.

The label lists screening and follow-up for intestinal polyps and monitoring for bowel obstruction, gallbladder or pancreatic problems and fluid overload. Increased absorption of some oral medicines may also require monitoring.

Sources for this section

What to ask about follow-up and access

Ask the intestinal rehabilitation team which evaluations it coordinates and who adjusts IV support. FDA removed Gattex’s separate Risk Evaluation and Mitigation Strategy on August 26, 2026. The warnings and monitoring in the prescribing information still apply.

Takeda distributes Gattex through a limited specialty pharmacy network. For example, UnitedHealthcare’s commercial vendor list names Accredo and Caremark for Gattex under the pharmacy benefit. Ask your own plan which pharmacy it uses, what prior approval it requires and what you would owe for the first fill and refills.

Takeda Patient Support can coordinate with the dispensing pharmacy and describes copay assistance for eligible commercially insured patients enrolled in its program. Ask about eligibility and how much you would owe after any assistance.

Sources for this section

GLP-2 medicines still in clinical trials

Ironwood reported in November 2026 that STARS-2, a confirmatory phase 3 trial of apraglutide, was recruiting adults with short bowel syndrome and intestinal failure who depend on IV nutrition or fluids. It measures the change in weekly IV support volume over 24 weeks.

FDA requested more evidence after reviewing glepaglutide in 2024. The phase 3 EASE SBS 5 trial is evaluating changes in weekly IV support for adults with short bowel syndrome and intestinal failure. Both medicines remain investigational in the United States. Ask the intestinal rehabilitation team about current treatment options and whether a trial is relevant.

Sources for this section
Explore Gut Health & Digestion